We developed sub-100nm optical/MR/X-ray contrast-bearing theranostic nanoparticles (TNPs) based on Gold nanorod cores and Gd3+ oxide shells for interventional image-guided photothermal therapy (PTT). In this study, we explore the value of MRI for tracking TNP-mediated PTT response and distinguishing tumors from normal surrounding tissues in preclinical colorectal liver metastases (CLRM). The results showed that tumors with TNPs depict higher R2*-relaxivity compared to normal liver post-TNP mediated PTT, and this increase persists ten days post-therapy. Therefore, MRI contrast can be used for specifically targeting CRLM tumors, which enables delivering sufficient amount of light to the tumor and tracking the therapy response.
This abstract and the presentation materials are available to members only; a login is required.